-
Something wrong with this record ?
Effects of 2-chloroadenosine on cortical epileptic afterdischarges in immature rats
M. Pometlová, H. Kubová, P. Mares,
Language English Country Poland
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NR9184
MZ0
CEP Register
Digital library NLK
Full text - Část
Source
NLK
Free Medical Journals
from 2005 to 2013
- MeSH
- 2-Chloroadenosine administration & dosage pharmacology MeSH
- Anticonvulsants MeSH
- Electroencephalography drug effects MeSH
- Epilepsy, Tonic-Clonic drug therapy physiopathology MeSH
- Epilepsy drug therapy physiopathology MeSH
- Electrodes, Implanted MeSH
- Injections, Intraperitoneal MeSH
- Rats MeSH
- Cerebral Cortex drug effects physiopathology MeSH
- Motor Activity drug effects MeSH
- Rats, Wistar MeSH
- Aging physiology MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Adenosine may represent an endogenous anticonvulsant in the brain. This study focused on the possible anticonvulsant action of an adenosine agonist, 2-chloroadenosine, against cortical epileptic afterdischarges (ADs) in immature rats. Three age groups of rat pups with implanted electrodes were studied: 12-, 18- and 25-days-old. The compound, 2-chloroadenosine, was injected after the first successful stimulation at doses of 1, 4 or 10 mg/kg intraperitoneally, and stimulation at the same intensity was repeated three more times. Movements directly elicited by stimulation, as well as clonic seizures accompanying electroencephalography (EEG) ADs, were markedly suppressed in only the 18-day-old animals. The effects in the 12- and especially the 25-day-old rats were moderate. The duration of the ADs decreased in all three age groups with 2-chloroadenosine treatment, and the shortest AD duration was seen in the treated, 12-day-old rats. The AD suppression also lasted longer in this age group than it did in the older animals. After a brief suppression of the second AD, the treated, 25-day-old group exhibited a significant AD rebound during the third and fourth stimulations. Taken together, our data show that 2-chloroadenosine exhibits an anticonvulsant effect that is dose- and age-dependent.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025826
- 003
- CZ-PrNML
- 005
- 20140717113626.0
- 007
- ta
- 008
- 120817s2010 pl f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/s1734-1140(10)70243-7 $2 doi
- 035 __
- $a (PubMed)20360616
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Pometlová, Marie $u Charles University, Third Medical School, Department of Normal, Pathological and Clinical Physiology, Ke Karlovu 4, CZ-12000 Prague 2, Czech Republic.
- 245 10
- $a Effects of 2-chloroadenosine on cortical epileptic afterdischarges in immature rats / $c M. Pometlová, H. Kubová, P. Mares,
- 520 9_
- $a Adenosine may represent an endogenous anticonvulsant in the brain. This study focused on the possible anticonvulsant action of an adenosine agonist, 2-chloroadenosine, against cortical epileptic afterdischarges (ADs) in immature rats. Three age groups of rat pups with implanted electrodes were studied: 12-, 18- and 25-days-old. The compound, 2-chloroadenosine, was injected after the first successful stimulation at doses of 1, 4 or 10 mg/kg intraperitoneally, and stimulation at the same intensity was repeated three more times. Movements directly elicited by stimulation, as well as clonic seizures accompanying electroencephalography (EEG) ADs, were markedly suppressed in only the 18-day-old animals. The effects in the 12- and especially the 25-day-old rats were moderate. The duration of the ADs decreased in all three age groups with 2-chloroadenosine treatment, and the shortest AD duration was seen in the treated, 12-day-old rats. The AD suppression also lasted longer in this age group than it did in the older animals. After a brief suppression of the second AD, the treated, 25-day-old group exhibited a significant AD rebound during the third and fourth stimulations. Taken together, our data show that 2-chloroadenosine exhibits an anticonvulsant effect that is dose- and age-dependent.
- 650 _2
- $a 2-chloradenosin $x aplikace a dávkování $x farmakologie $7 D015762
- 650 _2
- $a stárnutí $x fyziologie $7 D000375
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antikonvulziva $7 D000927
- 650 _2
- $a mozková kůra $x účinky léků $x patofyziologie $7 D002540
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a implantované elektrody $7 D004567
- 650 _2
- $a elektroencefalografie $x účinky léků $7 D004569
- 650 _2
- $a epilepsie $x farmakoterapie $x patofyziologie $7 D004827
- 650 _2
- $a epilepsie tonicko-klonická $x farmakoterapie $x patofyziologie $7 D004830
- 650 _2
- $a injekce intraperitoneální $7 D007274
- 650 _2
- $a pohybová aktivita $x účinky léků $7 D009043
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kubová, Hana
- 700 1_
- $a Mares, Pavel
- 773 0_
- $w MED00165879 $t Pharmacological reports : PR $x 1734-1140 $g Roč. 62, č. 1 (2010), s. 62-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20360616 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20140717113927 $b ABA008
- 999 __
- $a ok $b bmc $g 947868 $s 783172
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 62 $c 1 $d 62-7 $i 1734-1140 $m Pharmacol. Reports $n Pharmacol. Rep. $x MED00165879
- GRA __
- $a NR9184 $p MZ0
- LZP __
- $a Pubmed-20120817/10/03